Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TRVN logo TRVN
Upturn stock ratingUpturn stock rating
TRVN logo

Trevena Inc (TRVN)

Upturn stock ratingUpturn stock rating
$0.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TRVN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $5

1 Year Target Price $5

Analysts Price Target For last 52 week
$5 Target price
52w Low $0.25
Current$0.28
52w High $7.85

Analysis of Past Performance

Type Stock
Historic Profit -1.11%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.24M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 1
Beta 0.4
52 Weeks Range 0.25 - 7.85
Updated Date 08/16/2025
52 Weeks Range 0.25 - 7.85
Updated Date 08/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -48.89

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1970.67%

Management Effectiveness

Return on Assets (TTM) -62.39%
Return on Equity (TTM) -1014.58%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 24343860
Price to Sales(TTM) 0.44
Enterprise Value 24343860
Price to Sales(TTM) 0.44
Enterprise Value to Revenue 44.59
Enterprise Value to EBITDA 0.21
Shares Outstanding 863788
Shares Floating 858208
Shares Outstanding 863788
Shares Floating 858208
Percent Insiders 0.48
Percent Institutions 9.98

ai summary icon Upturn AI SWOT

Trevena Inc

stock logo

Company Overview

overview logo History and Background

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders. Founded in 2007, Trevena has primarily focused on opioid-based drugs with reduced side effects.

business area logo Core Business Areas

  • Pain Management: Trevena develops and commercializes pain management therapies, with a focus on biased ligands targeting G protein-coupled receptors (GPCRs).

leadership logo Leadership and Structure

The leadership team includes Carrie Bourdow, the President and CEO. The company operates with a typical biopharmaceutical structure, involving research, development, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Olinvyk (oliceridine): Olinvyk is an IV opioid approved for the management of acute pain in adults when alternative treatments are inadequate. Market share is small relative to established opioid analgesics. Competitors include morphine, fentanyl, hydromorphone, and other opioid-based pain medications from companies like Pfizer, Johnson & Johnson, and Mallinckrodt.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the segment focused on pain management, is characterized by intense competition, stringent regulatory oversight, and evolving treatment paradigms including alternative pain therapies.

Positioning

Trevena aims to differentiate itself through biased ligand technology, seeking to offer pain relief with fewer side effects. This positions them as an innovator in the pain management space.

Total Addressable Market (TAM)

The total addressable market for acute pain management is substantial, estimated to be several billion USD annually. Trevena's positioning is focused on capturing a segment of this market with a safer opioid alternative.

Upturn SWOT Analysis

Strengths

  • Novel biased ligand technology
  • Olinvyk FDA approval
  • Focused pipeline

Weaknesses

  • Limited commercial resources
  • Dependence on a single product (Olinvyk)
  • History of operating losses

Opportunities

  • Expansion of Olinvyk usage
  • Partnerships for commercialization
  • Development of additional biased ligand therapies

Threats

  • Competition from established opioids
  • Generic entry
  • Regulatory changes impacting opioid prescribing

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • JNJ
  • MNK

Competitive Landscape

Trevena's competitive advantage lies in its biased ligand technology. However, it faces significant competition from larger, more established pharmaceutical companies with broader portfolios and greater commercial reach.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been minimal due to the development stage of the company and the recent launch of Olinvyk.

Future Projections: Future growth depends on successful commercialization of Olinvyk and potential pipeline development. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include commercialization efforts for Olinvyk and exploration of partnerships.

Summary

Trevena is a small biopharmaceutical company with a novel technology and an FDA-approved product, Olinvyk. It struggles with limited commercial resources and faces intense competition from established pharmaceutical giants. Future success hinges on Olinvyk's market adoption and pipeline development. Investors should watch for partnerships and cash burn rate.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q)
  • Company Investor Relations
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Trevena Inc

Exchange NASDAQ
Headquaters Chesterbrook, PA, United States
IPO Launch date 2014-01-31
President, CEO & Chairman Ms. Carrie L. Bourdow
Sector Healthcare
Industry Biotechnology
Full time employees 23
Full time employees 23

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.